Vision X
Vision X (维视艾康特) is a Shanghai-based Chinese medical device company that develops, manufactures, and sells NMPA Class III ophthalmic products — including Ortho-K lenses, domestically developed scleral lenses, myopia control spectacle lenses, optical biometers, and care solutions — serving hospitals, eye clinics, and patients across China.
- Company typePrivate
- Founded2018
- HeadquartersZhuhai, China
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vision X does
Vision X (维视艾康特) is a Shanghai-headquartered, venture-backed Chinese ophthalmic medical device company founded in 2018 by Li Xiaowei (formerly of Alcon and Essilor Optics) and Fu Xiaoyang (former founder of medical device CRO Zhutong). The company develops, manufactures, and commercializes a vertically integrated portfolio of NMPA Class III ophthalmic devices and care products organized across five segments: myopia management (Ortho-K lenses, H.O.R.I. defocus spectacle lenses, silicone hydrogel multifocal soft lenses), irregular astigmatism and ocular surface health (scleral lenses — China's first domestically developed — and RGP lenses), ophthalmic diagnostic instruments (optical biometer with big-data analytics), lens care solutions (preservative-free sterile saline, multi-purpose rigid contact lens care solution), and soft contact lenses under the Mu Guang Li (沐光里) brand. Proprietary technology pillars include the H.O.R.I. (Hexagon Optimized Reticular Integration) grid-array optimization technology for myopia control, a four-zone scleral lens architecture with independently adjustable zones, ACT design for Ortho-K lenses, and an AI-powered fitting engine claiming ≥95% accuracy on corneal-topography-driven parameter ordering.
The company makes money primarily through one-time hardware sales of medical devices (Ortho-K, scleral, RGP lenses, spectacle lenses, diagnostic instruments) to hospitals and clinics, with growing repeat-purchase revenue from consumable care solutions (sterile saline, multi-purpose care solution) and soft contact lenses. Go-to-market combines direct enterprise field sales targeting top-tier ophthalmology hospitals for clinical validation and commercial supply (including KOL partnerships with Wenzhou Medical University Eye Hospital, Fudan University Eye Hospital, Tianjin Eye Hospital, and Peking University People's Hospital) with a nationwide distributor/dealer network for broader hospital and clinic penetration. Pricing is not publicly disclosed and is quoted case-by-case through sales representatives and distributors.
Vision X is registered as 维视艾康特(广东)医疗科技股份有限公司 (Guangdong) and operates manufacturing facilities across Shanghai (rigid lenses, headquarters), Hangzhou (diagnostic instruments), Ningbo, and Zhuhai (ocular care solutions), supported by wholly owned operating subsidiaries in each city. The company has raised multiple funding rounds from Angel through Series B+ (cumulative funding described in sources as 'exceeding 100 million RMB,' achieving unicorn status post-Series A), with investors including Sequoia Capital China (Series A lead), Sherpa Healthcare Partners, Fosun Venture Capital, Pine Venture Capital, YuanSheng Investment, Hengqin Financial Investment, and — per Crunchbase — Temasek and Lake Bleu Capital as cross-over participants. In 2023 it was designated a Shanghai Key Service Unicorn Potential Enterprise by the Shanghai Municipal Government and was named among the Top 10 Medical Device Investment Cases by Touzhong.com and the Top 50 Healthcare Investment Value Companies by CHC Medical.
Vision X firmographics
Firmographics- Name
- Vision X
- Legal name
- 维视艾康特(广东)医疗科技股份有限公司
- Website
- https://icomfit.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Vision X (维视艾康特) is a Shanghai-based Chinese medical device company that develops, manufactures, and sells NMPA Class III ophthalmic products — including Ortho-K lenses, domestically developed scleral lenses, myopia control spectacle lenses, optical biometers, and care solutions — serving hospitals, eye clinics, and patients across China.
- Ownership category
- akta.pro rank
Vision X industry classification
Industry- Product category
- Ophthalmic Medical Devices
- NAICS
- Ophthalmic Goods Manufacturing (339115)
- SIC
- Ophthalmic Goods (3851)
- akta.pro primary industry
- Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions) (HLAHAJAE)
- akta.pro secondary industries
- Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment) (HLAHAJAD), Comprehensive Eye Exams & Vision Care (HLAKAKAA)
Keywords
Where Vision X is headquartered
LocationHeadquarters
- HQ city
- Zhuhai
- HQ country
- China
- HQ region
- Asia
Offices5 records
Markets served
Vision X business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Medical Device Sales — Myopia Control Solutions: Revenue from sale of myopia control products including orthokeratology lenses and related care solutions. One-time purchase model with repeat purchase of consumables/care products.
- Medical Device Sales — Ophthalmic Equipment: Revenue from sale of ophthalmic diagnostic and treatment equipment to hospitals and clinics.
- Medical Device Sales — Ocular Surface Management: Revenue from scleral lenses and ocular surface disease management devices for irregular cornea and dry eye patients.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Vision X product offering
Product offeringCore offering
Vision X (维视艾康特) designs, manufactures, and sells ophthalmic medical devices and eye care solutions, including orthokeratology (Ortho-K) lenses, rigid gas permeable (RGP) scleral lenses, defocus spectacle lenses for myopia control, silicone hydrogel soft contact lenses, lens care solutions, and optical biometric diagnostic equipment. The company serves hospitals, eye clinics, and medical institutions in China through direct enterprise sales and a nationwide distributor network.
Product overview
Vision X (维视艾康特) offers a comprehensive portfolio of ophthalmic medical devices and eye care solutions organized into five business segments: (1) Myopia Management - including 艾康菲®角膜塑形镜 (Ortho-K lenses with AI fitting), 艾沐皓锐®离焦框架镜 (H.O.R.I. spectacle lenses), and 硅水凝胶多焦软镜; (2) Irregular Astigmatism and Ocular Surface Health - including 艾康菲®硬性巩膜接触镜 (scleral lenses, first domestically developed) and 艾康菲®硬性角膜接触镜 (RGP lenses); (3) Ophthalmic Diagnostic Instruments - including 微晓远山®眼科光学生物测量仪 with big data analytics; (4) Lens Care Solutions - including 艾康舒®无菌生理盐水 and 洗眼液; and (5) Soft Contact Lenses - including 硅水凝胶单焦软镜 and 多焦软镜 under the 沐光里 brand. The company operates as a total vision care solutions provider, from front-end diagnostic equipment through vision correction products to care solutions.
Differentiator
Problem solved
Functional benefit
Brands
- 艾康菲 (iComfit): 硬性巩膜接触镜、角膜塑形镜、RGP等核心接触镜产品品牌
- 艾康舒 (iComsuit)
- 艾沐皓锐 (H.O.R.I.)
- 微晓远山
- 沐光里
Products and services
- iComfit® Rigid Scleral Contact Lenses (艾康菲®硬性巩膜接触镜) Class III rigid gas permeable scleral lens with four-zone design for correcting irregular corneal astigmatism and high refractive errors in patients with keratoconus, post-LASIK ectasia, and corneal scarring. Sold to ophthalmology hospitals and clinics.
- iComfit® Ortho-K Lenses (艾康菲®角膜塑形镜) Night-wear orthokeratology contact lenses that temporarily reshape the cornea to correct myopia, indicated for myopia up to -4.00D and astigmatism up to 1.50D. Features ACT design, SWET technology, and AI-powered corneal topography fitting for myopia control in pediatric and adolescent populations. Sold to eye hospitals and clinics.
- H.O.R.I. Myopia Control Spectacle Lenses (艾沐皓锐®离焦框架镜) Defocus spectacle lenses for myopia control in children and teenagers, using H.O.R.I. (Hexagon Optimized Reticular Integration) technology with a 67% filling ratio grid design featuring integrated mesh, fractal boundary, and full symmetry. Sold through eye hospitals, optometry clinics, and optical retailers.
- iComfit® RGP Contact Lenses (艾康菲®硬性角膜接触镜) Daily-wear rigid gas permeable contact lenses for correcting myopia and hyperopia, featuring smooth edge design, high oxygen permeability, and improved corneal fit. Sold to ophthalmology clinics and eye hospitals.
- Wei Xiao Yuan Shan® Optical Biometer (微晓远山®眼科光学生物测量仪)
Companies that use Vision X
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
Vision X technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Vision X partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and major.
- Wenzhou Medical University Eye Hospital (温州医科大学附属眼视光医院)coreLeading ophthalmology hospital and clinical trial partner for Vision X's myopia control and scleral lens products. Provides clinical validation, KOL engagement, and academic credibility.
- Fudan University Eye Hospital (复旦大学附属眼耳鼻喉科医院)coreTop-tier eye hospital affiliated with Fudan University serving as a key clinical trial site and academic partner for Vision X's orthokeratology and ophthalmic device development.
- Tianjin Eye Hospital (天津市眼科医院)majorMajor ophthalmology hospital in northern China collaborating with Vision X on clinical research and product development for specialized eye care solutions.
- Peking University People's Hospital (北京大学人民医院)majorLeading teaching hospital providing clinical research collaboration and academic endorsement for Vision X's ophthalmic products and technologies.
Scale indicators2 records
Recent moves8 records
Expansion highlights6 records
Vision X competitors and assessment
Company assessmentBroad incumbents
- Alcon: Global ophthalmic medical device and contact lens leader (Precision1, Dailies, Air Optix) and Vision X founder Li Xiaowei's prior employer. Operates broadly across the same ophthalmic device categories but at a global scale; sets the competitive benchmark for premium contact lens, surgical, and vision care products in China.
- Bausch + Lomb: Global contact lens, lens care, and ophthalmic pharmaceutical company with established presence across soft contact lenses, RGP, and lens care solutions in China. Directly competes with Vision X across multiple product lines including the iComsuit® care solution franchise.
- Johnson & Johnson Vision: World leader in disposable soft contact lenses (Acuvue franchise) and ortho-K (Acuvue Abiliti). Competes with Vision X in soft contact lenses, multifocal correction and myopia management categories in China.
- CooperVision: Global contact lens manufacturer (clariti, Biofinity, MiSight myopia control lens). MiSight 1 day is a direct competitor to Vision X's pediatric myopia management soft lens strategy in China.
Direct peers
- Euclid Systems: US-based pioneer of Ortho-K lens designs for myopia control, with established distribution in China through partnerships. Competes directly with Vision X's iComfit® Ortho-K Lenses for hospital channel adoption and clinical trial validation sites.
- Menicon: Japan-based leader in RGP and specialty contact lenses (including ortho-K and scleral designs), with direct presence in China. Closely comparable to Vision X in scleral lens technology depth and Ortho-K offerings, and a potential international expansion benchmark.
- Paragon Vision Sciences: Manufacturer of specialty contact lenses including CRT (Corneal Refractive Therapy) ortho-K designs and gas permeable lenses. Competes with Vision X across both Ortho-K and RGP lens categories, particularly in markets where its CRT brand has been licensed to Chinese partners.
- Ovctek (欧普康视): China's largest domestic orthokeratology (Ortho-K) lens manufacturer and a direct competitor to Vision X in the myopia control lens segment. Both companies target the same Chinese hospital and optometry clinic channels with prescription myopia management lenses and have overlapping clinical validation strategies with leading ophthalmology hospitals.
Emerging players
- Brighten Optix (明灏光学): Emerging Chinese player in ortho-K and defocus spectacle lenses, focused on the pediatric myopia control segment. Comparable to Vision X in scale and product overlap, and a direct domestic competitor for hospital channel partnerships.
Regional players
- Lucid Korea: South Korea-based manufacturer of Ortho-K lenses with growing presence in Asia. Comparable to Vision X's Ortho-K technology focus and serves as a regional benchmark for scleral lens and Ortho-K product strategy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Vision X compliance and trust
Trust signalCompliance5 records
Vision X financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vision X leadership team
Management profileNumber of profiles
Profiles4 records
Vision X subsidiaries and ownership
Company hierarchySubsidiaries3 records
Vision X funding detail
Funding detailFunding overview
Funding rounds1 record
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vision X M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vision X
What does Vision X do?
Vision X (维视艾康特) designs, manufactures, and sells ophthalmic medical devices and eye care solutions, including orthokeratology (Ortho-K) lenses, rigid gas permeable (RGP) scleral lenses, defocus spectacle lenses for myopia control, silicone hydrogel soft contact lenses, lens care solutions, and optical biometric diagnostic equipment. The company serves hospitals, eye clinics, and medical institutions in China through direct enterprise sales and a nationwide distributor network.
Is Vision X a public or private company?
Vision X is a private company. It is classified as venture growth investor backed and is currently operating.
When was Vision X founded?
Vision X was founded in 2018. It employs 51 to 100 people.
Where is Vision X based?
Vision X is headquartered in Zhuhai, China, in the Asia region.
How does Vision X make money?
Three revenue lines are on record. Medical Device Sales — Myopia Control Solutions are the primary driver. The others are medical Device Sales — Ophthalmic Equipment and medical Device Sales — Ocular Surface Management.
Who are Vision X's main competitors?
Broad incumbents on record are Alcon, Bausch + Lomb, Johnson & Johnson Vision and CooperVision. Direct peers are Euclid Systems, Menicon, Paragon Vision Sciences and Ovctek (欧普康视). Brighten Optix (明灏光学) is listed as an emerging player. Lucid Korea is listed as a regional player.
Does Vision X have an API?
No public API is recorded for Vision X.
What industry is Vision X in?
Vision X's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAE, Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions), with a secondary code of HLAHAJAD, Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment). Its NAICS code is 339115 and its SIC code is 3851.